Vanguard Asset Management’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCVX
Vanguard Asset Management's PCVX Position: Q3 2026 in Review
Vanguard Asset Management increased its Vaxcyte (PCVX) stake by 9.6% in Q3 2026, buying an estimated $646K and bringing the position to 126,094 shares worth $7.17M. The position accounts for ﹤0.01% of the portfolio, ranked #852.
Vanguard Asset Management first reported a position in PCVX in Q1 2026 and has held it in 3 quarters since. 356 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.
- Vanguard Asset Management held 126,094 shares of Vaxcyte worth $7.17M as of Q3 2026.
- Vanguard Asset Management bought 11,074 Vaxcyte shares in Q3 2026, an estimated $646K.
- Vaxcyte made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #852 holding.
- Vanguard Asset Management first reported a position in Vaxcyte in Q1 2026 and has held it in 3 quarters since.
- 356 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.